Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076   CADENCE PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts)Three Months EndedMarch 31,20132012Revenue:Product revenue, net

$
23,612$
8,004Total revenues

23,6128,004Costs and expenses:Cost of product sales

8,1674,246Amortization of patent license

336336Research and development

1,3631,511Selling, general and administrative

21,63523,531Other

50-Total costs and expenses

31,55129,624Loss from operations

(7,939)(21,620)Other income (expense), net

6,576(1,053)Net loss

$
(1,363)$
(22,673)Basic and diluted net loss per share

$
(0.02)$
(0.27)Shares used to compute basic anddiluted net loss per share

85,67285,519 CADENCE PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(in thousands)March 31,December 31,20132012(unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments 

$
4,240$
2,072Restricted cash 

640640Accounts receivable, net 

8,9086,152Inventory 

6,0836,498Prepaid expenses and other current assets 

2,0411,154Total current assets

81,91276,516Property and equipment, net

1,9051,967Intangible assets, net

11,75412,090Other assets

907,106Total assets

$
95,661$
97,679Liabilities and Stockholders' Equity Current liabilities:Accounts payable 

$
5,808$
5,796Accrued liabilities 

12,53212,969Deferred revenue 

-2,234Current debt, less discount 

2,552-Total current liabilities

20,89220,999Other liabilities

23351Long-term debt, less discount

26,38828,818Total stockholders' equity

48,14847,811Total liabilities and stockholders' equity

$
95,661
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... pleased to announce that its three Promissory Note holders, ... advanced $ 100,000 each in July 2014 for a ... and related Coupons converted into 3,500,001 restricted common shares. ... coupon. Both the Note and the coupon were convertible ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... Calif., Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of peripheral vascular disease,announced today that ... quarter ended December 31, 2007, after the close of ... regular quarterly teleconference at 2:00 p.m. PT,/ 5:00 p.m. ...
... Two Development Milestones in its Ofatumumab ... Collaboration With GlaxoSmithKline., COPENHAGEN, January 21 ... second and third development milestones,for ofatumumab (HuMax-CD20(R)) under the terms ... of the collaboration of DKK 87.2 million,was triggered by treatment ...
... company insiders knowingly misrepresented the ... ... Sobol Shapiro filed a,proposed class-action lawsuit on behalf of CellCyte ... the company and chief executive officer Gary A.,Reys, background, causing ...
Cached Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Genmab Reaches Milestones in Ofatumumab Collaboration 2Genmab Reaches Milestones in Ofatumumab Collaboration 3Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
(Date:9/29/2014)... story from 2009, "human activities in this area of the ... oil is increasingly grown for use as a cooking oil ... It has become the most widely produced edible oil in ... surpass that of soybean oil. , The environmental effects of ... to grow the crop, and the preferred method is fire. ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... 2013 UT Southwestern Medical Center researchers report that ... to inflammatory disease, indicating that the production of a ... clock. The study published in the Nov. 8 ... pathway by which the body,s circadian clock controls the ...
... Science Foundation (NSF), in cooperation with interagency and ... awards under a program that supports multi- and ... and sustainability of the natural and living environment, ... the Arctic. Six projects have been ...
... URBANA, Ill. Despite a 12-year action plan calling for ... progress has been made, and there is no evidence that ... University of Illinois researchers have identified some of the biophysical ... "We are suggesting that a partnership of researchers work ...
Cached Biology News:UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3
Sheep Serum US Origin...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: